Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥64.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥64.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥46.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)602.40K
Market Cap
¥4.05B
Enterprise Value¥5.12B
Total Cash (Recent Filing)¥977.18M
Total Debt (Recent Filing)¥832.50M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.06
Shares Outstanding84,548,960
10 Day Avg. Volume594,170
30 Day Avg. Volume602,396
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Pharmaceutical FocusA focused oncology and hematology model can support specialized expertise, targeted development priorities, and durable positioning in clinically important markets. Regulatory and indication-expansion capabilities may also allow SymBio to extend the commercial life and addressable use of selected products over time.
High Gross MarginThe high gross margin indicates that marketed or developed products retain underlying economic value before operating expenses. If SymBio can control selling, research, and other overhead costs, this margin structure could provide a foundation for restoring profitability without requiring a fundamental change to its product strategy.
Meaningful Asset BaseA meaningful asset base provides some operating and financial resources while SymBio advances its pharmaceutical portfolio. Although the balance sheet is under pressure, these assets can support ongoing activity and preserve a degree of flexibility as management works to stabilize performance and commercial execution.
Bears Say
Revenue And Profitability DeteriorationRepeated revenue contraction and the shift from positive margins in 2021–2022 to deeply negative margins in 2023–2025 indicate a material deterioration in operating performance. Sustaining this trend would weaken scale, reduce funding available for development, and make a timely return to profitability more difficult.
Persistent Cash BurnNegative operating and free cash flow show that the business is not currently funding itself from operations. Continued cash burn can consume financial resources, increase reliance on external financing, and constrain investment in drug development or commercialization if losses persist through the coming quarters.
Leverage And Equity ErosionThe emergence of debt after several debt-free years, combined with shrinking equity, materially reduces financial flexibility. Higher leverage can increase financing pressure while accumulated losses limit the balance-sheet cushion available to absorb further weak results or fund longer development timelines.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥46.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥4.05B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Oct 29, 2026 which is in 5 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Jul 30, 2026. The company reported -¥15 earnings per share for the quarter.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 84,548,960 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥15 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―